#AACR: Bristol-Myers tunes out static, broadcasts impressive results for Opdivo/Yervoy lung cancer combo
CHICAGO — Bristol-Myers Squibb $BMY ran smack dab into a high level of professional static when it changed up its study design for Checkmate-227, a pivotal …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
